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Abstract
Background: Approximately 70,000 patients/year undergo surgery for repair of a fractured hip in the United
Kingdom. This is associated with 30-day mortality of 9% and survivors have a considerable length of acute hospital
stay postoperatively (median 26 days). Use of oesophageal Doppler monitoring to guide intra-operative fluid
administration in hip fracture repair has previously been associated with a reduction in hospital stay of 4-5 days.
Most hip fracture surgery is now performed under spinal anaesthesia. Oesophageal Doppler monitoring may be
unreliable in the presence of spinal anaesthesia and most patients would not tolerate the probes. An alternative
method of guiding fluid administration (minimally-invasive arterial pulse contour analysis) has been shown to
reduce length of stay in high-risk surgical patients but has never been studied in hip fracture surgery.
Methods: Single-centre randomised controlled parallel group trial. Randomisation by website using computer
generated concealed tables. Setting: University hospital in UK. Participants: 128 patients with acute primary hip
fracture listed for operative repair under spinal anaesthesia and aged > 65 years. Intervention: Stroke volume
guided intra-operative fluid management. Continuous measurement of SV recorded by a calibrated cardiac output
monitor (LiDCOplus). Maintenance fluid and 250 ml colloid boluses given to achieve sustained 10% increases in
stroke volume. Control group: fluid administration at the responsible (blinded) anaesthetist’s discretion. The
intervention terminates at the end of the surgical procedure and post-operative fluid management is at the
responsible anaesthetist’s discretion. Primary outcome: length of acute hospital stay is determined by a blinded
team of clinicians. Secondary outcomes include number of complications and total cost of care.
Funding NIHR/RfPB: PB-PG-0407-13073.
Trial registration number: Trial registration: Current Controlled Trials ISRCTN88284896.
Background
Approximately 70,000 patients per year undergo surgery
for repair of a fractured hip in the United Kingdom (UK)
[1], at a cost of £25,424 per patient [2]. Hip fracture is
associated with a high mortality (approximately 9% at
30 days postoperatively)[3] and a considerable length of
acute hospital stay (median stay 26 days) [4]. Mortality
and length of stay in hospital have remained relatively
constant over recent years. The majority of patients with
hip fracture are elderly women (median age 81 years,
73% female) [2], and the number of these patients will
likely increase in the future in line with the changes in
the United Kingdom population [5-7].
Patients with hip fracture suffer from a variety of fluid
losses following their injury. They spend a variable
amount of time unable to drink or eat, due to immobility
at the time of injury and fasting prior to surgery. The
fracture itself will haemorrhage internally to a variable
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during and after surgery [8]. Many elderly patients are
taking medications which promote fluid loss (mainly
diuretics) [9]. For these reasons most patients are given
intravenous fluid on admission. During surgery the
anaesthetist usually gives intravenous fluids based upon
clinical judgement of all the above factors and clinical
signs such as heart rate and blood pressure.
The amount of intravenous fluid patients are given
before, during and after surgery, may have prolonged effects
on outcome. Studies in non-orthopaedic surgery suggest
that protocol driven (or goal directed) intra-operative fluid
administration is associated with improved outcome and
reduction in hospital stay [10,11]. The aim of goal-directed
fluid therapy is to optimise the amount of blood in the
veins filling the heart and therefore optimise stroke volume
(volume of blood leaving the heart with every heart beat),
cardiac output (volume of blood pumped by the heart per
minute) and thereby oxygen delivery to the tissues. A num-
ber of studies suggest that derangement of cardiac output is
one factor that is strongly associated with post-operative
complications and death [12]. Previous studies of patients
undergoing surgery for fractured hip have shown that using
a Doppler ultrasound probe placed in an anaesthetised
patient’s oesophagus to measure the velocity of blood
flow in the aorta to help guide fluid administration, resulted
in a reduced hospital stay from 17 to 12 days [13-15].
Administering a fixed dose of additional fluid without car-
diac output monitoring does not seem to be of benefit [16].
However, many patients receive a spinal anaesthetic for hip
surgery, a technique which is associated with a lower risk of
heart attack, confusion and low blood oxygen levels com-
pared to general anaesthesia [17]. During spinal anaesthe-
sia, the patient remains awake or lightly sedated and
therefore would be unlikely to tolerate an ultrasound probe
in their oesophagus [18]. The ultrasound measurements of
cardiac output may also be unreliable when a spinal anaes-
thetic is used [19].
An alternative to the Doppler ultrasound probe is esti-
mation of cardiac output by analysis of the waveform of
the arterial blood pressure pulse. This technique has
become more practical and widespread in recent years due
to advances in technology. It is a minimally invasive techni-
que, well tolerated in awake or sedated patients, which ana-
lyses arterial pressure changes during the cardiac cycle,
allowing calculation of stroke volume and cardiac output
[20]. This technique has been used to guide the volume of
intravenous fluid administered to patients at high risk of
complications after major surgery, and when used resulted
in a shorter hospital stay [21]. It has never been studied in
patients having hip fractures repaired to the author’s
knowledge, based on literature review (including an
updated systematic search based upon Parker [16], and dis-
cussion with peers). In the period since the original papers
demonstrating benefits of goal-directed fluid therapy in hip
fracture, other practices have also changed. More patients
are given intravenous fluids as soon as they are admitted,
the time to surgery has decreased and more patients have
surgery performed under spinal anaesthesia. It is therefore
appropriate to investigate whether goal-directed fluid man-
agement is of benefit in contemporary hip fracture care.
In addition, to the authors’ knowledge the changes in
the heart and blood vessels produced by a spinal anaes-
thetic in patients with fractured hips have never been
characterised fully. Patients with a fractured hip are often
elderly with numerous associated medical problems.
Knowledge of how spinal anaesthetics affect the heart
and blood vessels in this high risk population may help
guide how to best maintain the patient’s blood pressure
and blood flow during surgery.
Methods
Study Objectives
Primary Aims
To investigate whether stroke volume (SV) guided fluid
therapy for patients undergoing fractured hip surgery
under a spinal anaesthetic affects:
1) the time the patient spends in acute care in
hospital;
Secondary Aims
2) To investigate if using SV guided fluid therapy a
patient receives while having their fractured hip
repaired under a spinal anaesthetic affects:
a. the time until the patient is medically well
enough to be discharged from hospital;
b. the number of postoperative complications;
c. the total amount of intravenous fluid given
during surgery;
d. the total cost of care.
3) To characterise the changes in the way the heart
and blood vessels work after a spinal anaesthetic, as
measured by minimally-invasive cardiac output
monitoring.
Study Design
This is a prospective, single-centre, randomised, parallel
group controlled trial conducted at the Queens Medical
Centre campus of Nottingham University Hospitals,
Nottingham, UK. Study recruitment commenced on 9
th
September 2009 when the first patient was randomised.
Recruitment is ongoing (August 2011).
Randomization and Blinding
Randomisation (on a one-to-one allocation basis) is via a
password-protected web based randomisation service
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sequence not revealed until datalock. To achieve similar
numbers and balance on risk, patients will be stratified
according to predicted 30-day mortality (2 levels). The
Nottingham Hip Fracture Score [22-24], is used to iden-
tify patients with low (≤ 10%) or high (> 10%) risk of
mortality within 30-days. Subjects are randomised on
arrival in the anaesthetic room to minimise the risk of
medical or surgical cancellation after randomisation.
Patients, orthopaedic surgeons and ward staff are
blinded to the treatment intervention. The operative
attending anaesthetist is not blinded to the treatment arm,
but is blinded to the cardiac output measurements for the
control arm. Postoperative data collection is by a research
nurse blinded to treatment allocation. The decision that a
patient is medically fit for discharge is made by the multi-
professional team when all are satisfied that the participant
has no ongoing needs for acute hospital care. This team is
blinded to participant allocation.
Selection and withdrawal of participants
Recruitment
Participants are identified by their presence on surgical
lists and are recruited from the trauma wards. The investi-
gator informs the participant or their nominated represen-
tative (other individual or other body with appropriate
jurisdiction), of all aspects pertaining to participation in
the study. Participation in the study is for the duration of
the anaesthetic and surgical procedure, which is approxi-
mately two hours. The study intervention is complete at
the end of the surgical procedure, though all participants
have a follow-up visit the next day to ensure no problems
have arisen. The medical notes are reviewed following hos-
pital discharge for in-hospital complications and medica-
tion use.
Participants are informed that entry into the trial is
voluntary and that they are free to withdraw at anytime
without effect on subsequent care. Data on time to dis-
charge and postoperative mortality are collected routinely
and separate from this study. These outcome data are
therefore available for all randomised participants.
Included in the trial are adults incapable of providing
their own consent, since a large proportion of potential
subjects will be acutely or chronically confused (around
30%). Exclusion of these patients from the trial would
severely limit the applicability of results to clinical practice,
since these patients are more likely to die, remain in hos-
pital for longer, and have more complications [22,25-27].
Patients from whom consent cannot be obtained due to
a language barrier are not recruited to the study. This is
due to the emergency nature of the surgery meaning that
it would not be practical to arrange for the provision of
translation services. In practice this is a very small propor-
tion of the total elderly population in the study centre.
Inclusion criteria
1. Patients listed for surgical repair of fracture neck of
femur under spinal anaesthesia
2. Aged > 65 years
Exclusion criteria
1. Planned general anaesthetic
2. Severe valvular heart disease previously shown on
echocardiography (reduces reliability of monitor
measurements)
3. Taking lithium (interferes with calibration of
monitor)
4. Multiple injuries requiring operative management
5. Revision surgery or total hip arthroplasty for frac-
tured neck of femur (a different patient/surgical
population)
6. Not admitted to hospital through the emergency
department
Informed consent
The capacity for consent is assessed routinely by the
orthopaedic team, who decide whether the patient is com-
petent to provide consent for the surgical procedure. If
they deem the patient is unable to consent for their sur-
gery, then the patient will be deemed incapable of provid-
ing consent to enter the study, and assent from their next
of kin is sought (or nominated consultee). The capacity for
consent may fluctuate in the population being studied. A
member of the research team also performs an additional
check of the participant’s ability to consent, immediately
prior to starting the study. All members of the research
team are trained at taking consent in accordance with
ICH-GCP guidance [28].
All patients are visited postoperatively. If the patient had
h a dat r a n s i e n ti m p a i r m e n to f their ability to consent,
which has subsequently resolved, retrospective consent is
sought from the patient to use their data in the study. If
the patient declines, date of discharge and postoperative
mortality data are collected as part of routine clinical man-
agement and so will be available for analysis. The same
would occur if contact with the next of kin pre-operatively
had not been possible. If the next of kin subsequently
declined assent, the patient data would once again be
withdrawn from the study.
Measurement of cardiac output
Monitoring of the key cardiovascular variables of blood
pressure and cardiac output (volume of blood pumped by
the heart per minute) is common in patients at high risk
of intra-operative and postoperative complications. One
such method employed is the LiDCOplus (LiDCO Ltd,
Cambridge, UK). This device allows calibrated, continu-
ous, real-time monitoring of cardiac output on a beat-to-
beat basis. The LiDCOplus cardiac output method of
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method of measuring cardiac output, which is the stan-
dard method of measuring cardiac output [29,30]. The
only equipment required is a peripheral cannula in a vein
and an arterial line (a small cannula inserted into an
artery that is routinely used in high risk patients).
A small dose of lithium chloride (0.15 mmol) is injected
through the venous cannula. This is a very small dose of
lithium, which has no known pharmacological effect [31].
Lithium has been used for the measurement of cardiac
output for many years without any side effects being
reported. A lithium concentration-time curve is measured
by withdrawing 5 ml of blood past a lithium sensor
attached to the patient’s existing arterial line and the
monitor then calculates the cardiac output from the area
of the primary dilution curve [32,33].
After this initial calibration, beat-to-beat measurements
of cardiac output are made by analysing changes in the
arterial pressure waveform. The device does not need
recalibrating for at least 8 hours [29]. The LiDCOplus
monitor provides values for cardiac output, systemic vas-
cular resistance, mean arterial pressure, heart rate and left
v e n t r i c l es t r o k ev o l u m e .T h ese are adjusted for patient
weight and height. As measurements of these variables are
made on a beat-to-beat basis, the LiDCOplus is an ideal
device for measuring changes in cardiovascular variables
to interventions such as fluid boluses.
This method of cardiac output measurement has been
shown to be as accurate as the thermodilution method
employed by pulmonary artery flotation (Swan-Ganz)
catheters [32,33] and avoids the complications associated
with their insertion and use. The LiDCOplus system is
also quicker and easier to set up then than pulmonary
artery catheter systems, which have previously been
thought of as the gold standard of cardiac output measure-
ment devices. The LiDCOplus monitor remains accurate
even if the arterial waveform becomes over- or under-
damped [34] or if regional anaesthetic techniques (such as
spinal or epidural anaesthesia) are used [35].
Study Intervention
On arrival in the anaesthetic room, all participants have an
arterial line sited at the wrist using local anaesthetic and
an arterial blood sample taken (to determine sodium and
haemoglobin concentrations for calibration of the LiDCO-
plus monitor). A cannula is inserted into a peripheral vein
for calibration purposes and to allow fluid administration,
if there is not an adequate one already in place. The arter-
ial line is then connected to the LiDCOplus machine and
calibration performed according to the manufacturer’s
guidelines, using a bolus intravenous injection of lithium
[36]. Routine anaesthetic monitoring is instituted by the
attending anaesthetist. The spinal anaesthetic is then per-
formed and the patient remains in the anaesthetic room
for at least 10 minutes to allow collection the post-spinal
anaesthetic data from the LiDCOplus monitor. The
patient is then taken into theatre once the anaesthetist is
satisfied that the spinal anaesthetic is adequate for surgery.
The management of fluids during the operation differs
between the study group and the control group. The
control group have the type, amount and rate of their
intravenous fluids determined by the anaesthetist, in
accordance with their usual practice. The anaesthetist is
blinded to the LiDCOplus measurements by placing the
LiDCO screen where it is not visible and turning off the
arterial waveform display. All intra-operative fluid
boluses and drugs administered by the anaesthetist,
including timings, are recorded by the Investigator.
The study group have their fluids given according to
the study protocol, based upon LiDCOplus measure-
ments. The participants in this group receive a mainte-
nance fluid of compound sodium lactate solution at a
rate of 1.5 ml kg
-1 h
-1. In addition they may be given 250
ml boluses of a colloid fluid, determined by the LiDCO-
plus measurements of stroke volume. Fluid boluses are
given until the stroke volume to achieve a sustained 10%
increase from the baseline (pre-operative) readings.
Further boluses are given subsequently should the stroke
volume fall by clinically important amounts at any time
during the operation (see Figure 1). If the attending
anaesthetist feels there are clinical reasons to give more
or less fluid they can do so. If blood transfusion is
required packed red cells are given as the colloid. Other-
wise the colloid given is at the discretion of the anaesthe-
tist. Discretionary actions of the attending anaesthetist
are recorded.
The intervention is complete at the end of surgery. At
this point the LiDCOplus monitoring is stopped, and
the arterial cannula removed. The total amount of fluid
is recorded for both groups. Postoperative fluids pre-
scribed for participants are at the discretion of the
anaesthetist.
Standard care
All patients are admitted to dedicated trauma wards and
cared for in accordance with UK ‘Best Practice Tariff’
[37]. This includes: assessment by orthogeriatricians;
operation within 36 hours of admission; bone health
assessment. All patients are cared for under a hip frac-
ture care pathway which involves rapid assessment and
admission from the emergency department; intravenous
crystalloid infusions from time of admission and multi-
professional care and discharge planning. Operations are
performed in dedicated trauma theatres by consultants
in anaesthesia and orthopaedic trauma or senior trai-
nees. The Queen’s Medical Centre has undertaken con-
tinuous, systematic audit of its hip fracture care since
2001 [22-24].
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Data on cost of treatment will be calculated from drug
use, investigations (diagnostic imaging, ECGs, blood
tests) and from the clinical record, which includes stan-
dardised costs for physiotherapy, occupational therapy
and discharge planning. The cost of additional monitor-
ing required for each patient will also be taken into con-
sideration in the cost analysis. Data will be presented in
terms of total non-operative costs, costs per day and
excess costs attributable to treatment group.
Statistics
Data will be analysed by the research team in conjunc-
tion with a medical statistician, using latest versions of
StatXact software. There will be no interim analysis.
From previous examination of the Nottingham Hip
Fracture Database (which has over 7000 patients) it is
expected that the primary outcome, length of stay
(LOS), will be normally distributed following a log trans-
formation. Following transformation these data will be
analysed using ANOVA using the stratification risk cate-
gories. The primary outcome measure is time until
declared medically fit for discharge. Length of acute hos-
pital stay, superspell (total time in hospital including
rehabilitation) will be analysed similarly.
The secondary outcomes of complications, residence
and place of discharge will be treated as categorical and
differences between the groups will be examined using
loglinear analysis. Mortality outcome will be analysed
using Kaplan-Meier mortality curves and log rank tests..
All secondary variables will the presented using
descriptive statistics. In addition to the calculated values,
confidence intervals and odds-ratios will be presented
when appropriate. All clinical information including all
adverse events will be presented in full. All secondary
analyses will be interpreted with caution as the sample
10% increase in stroke 
volume sustained 
Stroke volume 
decreased 
Measure Stroke volume 
≥10% increase in 
stroke volume  
250ml 
bolus of 
colloid 
given 
< 10% increase in 
stroke volume 
Monitor stroke volume  Monitor stroke volume 
Stroke volume 
sustained 
Figure 1 Flow chart for administration of colloid boluses in the intervention group. Changes in stroke volume are used to guide the
administration of colloid boluses. The aim is give colloid boluses to achieve cardiac filling near the top of the Starling curve. The algorithm is
interpreted in the light of clinical conditions.
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However, the level of power associated with secondary
results will be investigated.
Sample size and justification
Previous studies of optimisation strategies have demon-
strated approximately 30% reduction on acute length of
stay or time until medically fit to discharge and
approaches towards 50% reductions in complications in
survivors.
Length of acute hospital stay in our unit is consistently
around 17 days (SD 4.9 days), so to find a 3 day reduction
in LOS in survivors would require 58 patients in each
group with 90% power and a = 0.05. Assuming a 10%
drop out rate (conversion to general anaesthesia, opera-
tive cancellation after randomisation etc.) we aim to ran-
domize 64 subjects in each group. This would also
provide the same power to find a 50% reduction in com-
plication rates between the two groups. The study will
not be powered to demonstrate differences in mortality
(a 50% reduction in 30-day mortality from 10% to 5%,
would require around 450 patients in each group).
Definition of datasets analysed
Safety set: All randomised participants who received
LiDCOplus monitoring during surgery receive at least
one dose of the study drug.
Full Analysis set: All randomised participants, who
received LiDCOplus monitoring during surgery and for
whom at least death and discharge date are available.
Per protocol set: All participants in the Full Analysis set
who are deemed to have no major protocol violations
that could interfere with the objectives of the study.
Efficacy will be assessed on both the full analysis set
and the per protocol set; not the Intention-to-treat set.
Safety summaries will be performed on the safety set
Reporting of adverse events
All adverse events will be recorded and closely monitored
until resolution, stabilisation, or until it has been shown
that the study treatment is not the cause. Participants
will be asked to contact the study site immediately in the
event of any serious adverse event. The Chief Investigator
shall be informed immediately of any serious adverse
events and shall determine seriousness and causality in
conjunction with any treating medical practitioners.
All treatment related serious adverse events will be
recorded and reported to the Research Ethics Commit-
tee as part of the annual reports. Unexpected serious
adverse events will be reported to the Research Ethics
Committee and Sponsor within the relevant timeframes.
The Chief Investigator shall be responsible for all
adverse event reporting.
Ethics Committee and Regulatory Approval
The trial will be conducted in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki, 1996 [38]; the principles of Good Clinical Prac-
tice [28], and the Department of Health Research Govern-
ance Framework for Health and Social care, 2005 [39].
Approval was obtained from the Nottingham Research
Ethics Committee (Reference Number 08/H0403/129)
and from the National Health Service Research and
Development department (Reference Number 08AN004).
The study was also registered with the National Institute
for Health Research (Reference Number PB-PG-0407-
13073) and IRCTN: 88284896 (29 April 2010). The study
is ongoing with the first participant randomised on 9
September 2009.
Discussion
Studies into peri-operative management of patients
undergoing surgery for hip fracture are lacking [40].
Anaesthetic interventions in the peri-operative manage-
ment of hip-fracture tend to occur within a short period
of time owing to the emergency nature of the surgery,
with surgical fixation recommended within 48 hours of
hospital admission [41]. This results in important time
constraints in the practical aspects of study conduct and
participant recruitment to any potential trial. Gaining
informed consent is consequently problematic, an issue
compounded by the large proportion of acutely and
chronically confused patients who present with hip frac-
ture: exclusion of such patients from the trial would
severely limit the applicability of the results to clinical
practice and thus measures are taken to allow their par-
ticipation, including the involvement of the next of kin
or responsible consultant.
There is no single outcome measure that is accepted
as the ‘gold-standard’ in hip fracture research. Length of
stay has financial implications and may act as a surro-
gate for medical complications [9] but is strongly
affected by local practices and availability of rehabilita-
tion and social services. Mortality is a definite end-
point. However some authors suggest that 50-75% of
hip fracture deaths following surgery are inevitable [42],
so mortality may not be amenable to significant reduc-
tion. Various studies have used mobility measures
[43,44] but by and large these are surrogates for actual
post-discharge function, and there is little consistency
between studies. Discharge destination again has large
financial and social implications but is strongly affected
by local practices, and is irrelevant to the sizeable min-
ority of patients who are admitted from nursing home
care [24].
Most studies into peri-operative interventions for frac-
tured hip repair report outcomes focusing on length of
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tion to length of hospital stay, our study includes time
to being medically fit for discharge as a primary out-
come measure. Both these outcome measures are col-
lected by members of the research team blinded to
treatment allocation. Although both primary outcomes
are relevant, they are affected by many other clinical
and non-clinical factors, including availability of phy-
siotherapy services, pre-fracture morbidity and mobility,
and family/social services support. The secondary end-
point in our study of post-operative complications is
aimed more specifically at determining the effects of the
anaesthetic intervention under investigation in the study.
Although the original studies of stroke volume guided
fluid therapy showed clinically important results there has
been variable uptake of the technology in UK clinical prac-
tice. This may reflect changes in clinical practice, such as
earlier surgery and prescription of routine intravenous
fluids before surgery, which might be expected to reduce
the fluid deficit by the time the patients arrive in theatre.
In addition the technology used in the original studies is
not suitable for use in patients who are awake. We there-
fore felt that it was timely to investigate this approach in
contemporary clinical practice. The choice of cardiac out-
put monitoring (LiDCOplus) in our study was pragmatic
based upon validity and availability. At this time there are
a limited number of calibrated minimally invasive devices
suitable for this purpose. Non- or minimally invasive
devices that do not require calibration are available and
may be used for goal-directed intra-operative fluid man-
agement, provided the alternative system has the ability to
accurately predict fluid responsiveness.
The potential implications of our results are important.
Approximately 80,000 patients per year undergo hip frac-
ture surgery in the UK. Ward costs contribute 84% of the
total cost of hospital expenditure of patients undergoing
such a procedure, at a rate £430 per patient per day [45].
If stroke volume guided fluid management results in a
reduction in hospital stay of 5 days, as demonstrated using
the Doppler ultrasound probe [13,14], the saving could be
around £2,150 per patient. This equates to a potential
national saving in the UK of around £150 million per year.
The reduction in duration of hospital stay is therefore one
potential way of minimising expenditure following hip
fracture.
H i pf r a c t u r ei sl i k e l yt ob e c o m ea ni n c r e a s i n gh e a l t h
issue within the UK [6,7], with associated economic impli-
cations, and a high mortality and morbidity allied to
patients who suffer such injury. Despite this there is a lim-
ited evidence base with regards to guidance of best prac-
tice. Our study aims to augment this evidence base and
improve the peri-operative management of patients pre-
senting with fractured hip.
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